Scientific Program
ABSTRACT SYMPOSIA LECTURES |
|||
VASCULAR BIOLOGY |
|||
| Signal Transduction in Vascular Cells: | |||
| Michael Mendelsohn (Boston, MA) | Estrogen receptor actions in the cardiovascular system | ||
| Regulation of Gene Expression in Vascular Cells | |||
| Philip Marsden (Toronto, CA) | Regulation of vascular endothelial gene expression: The role of epigenetics | ||
| Shear Stress, Rheology, and Mechanical Signaling Responses | |||
| Martin Schwartz (Charlottesville, VA) | Fluid shear stress signaling in endothelial cells : roles of integrins and extracellular matrix | ||
| Inflammation | |||
| Paul Fox (Cleveland, OH) | Post-transcriptional regulation of inflammatory gene expression | ||
| Blood Vessel Development | |||
| Victoria Bautch (Chapel Hill, NC) | Integrating cellular processes to make a blood vessel | ||
| Blood Vessel Development | |||
Holger Gerhardt (London, UK) |
Molecular control of angiogenic sprouting | ||
| Inflammation and Vascular Pathobiology | |||
| Ulrich von Adrian (Boston, MA) | Mechanisms and consequences of dendritic cell migration | ||
| Atherosclerosis | |||
| Timothy Hla (Farmington, CT) | Vascular cell signaling by sphingosine-1-phosphate: |
||
|
|||
| Factor VIII and VWF | |||
| Peter Lenting (Leiden, NL) | Biology of von Willebrand factor | ||
| Hemophilia and Rare Blood Disorders | |||
| Alok Srivastava (Vellore, IN) | Hemophilia and rare blood disorders | ||
| Women and Bleeding Disorders | |||
| Rezan Kadir (London, UK) | Women and bleeding disorders: New perspectives | ||
| New Products in Hemophilia and vWD | |||
| Claude Negrier (Lyon, FR) | Can we improve upon nature to design products with enhanced efficacy for treating hemophilia and von Willebrand disease? | ||
| von Willebrand disease | |||
| Zaverio Ruggeri (La Jolla, CA) | Structure and function of von Willebrand factor: Facts and myths | ||
| Neonatal/Pediatric Hemostasis | |||
| Anthony Chan (Hamilton, CA) | Neonates: Are they more prone to clotting or bleeding ? | ||
| Intracranial Hemorrhage | |||
| Thorsten Steiner (Heidelburg, DE) | Intracranial hemorrhage: threats and chances | ||
| Update on gene therapy | |||
| Amit Nathwani (London, UK) | Gene therapy for haemophilia B | ||
|
|||
| Extrinsic Pathway of Coagulation | |||
| Diego Mezzano (Santiago, CL) | Regulation of platelet-expressed tissue factor | ||
| Intrinsic Pathway of Coagulation | |||
| Jacky Ngo (Boston, MA) | Crystal structure of B-domain deleted factor VIII and implications for the formation of the tenase complex | ||
| Contact Pathway | |||
| Alvin Schmaier (Cleveland, OH) | Animal models of the plasma kallikrein/ kinin system: Modulation of arterial thrombosis | ||
| Cofactors | |||
| John S (Pete) Lollar (Atlanta, GA) | The immune response to factor VIII | ||
| Serpins/Inhibitors | |||
| George Broze (St. Louis, MO) | Protein Z and ZPI: An update | ||
| Protease Structure/Function | |||
| Rodney Camire (Philadelphia, PA) | Novel factor Xa variants for improving hemostasis in hemophilia | ||
| Fibrinogen/Fibrinolysis | |||
| Kathy Hajjar (New York, NY) | Fibrinolysis and cellular functions: Implications for health and disease | ||
| Regulation of Coagulation | |||
| Bernd Engelmann (Munich, DE) | Activation of tissue factor-triggered coagulation by protein disulfide isomerase | ||
|
|||
| Phosphatases and Platelet Activation | |||
| Stephen Watson (Birmingham, UK) | Comparison of the proximal events in glycoprotein receptor signaling in platelets | ||
| Platelet Biochemistry and Biology | |||
| Donna Woulfe (Philadelphia, PA) | Arrestin-2: Regulating platelet responses to agonist | ||
| Adhesion and Cohesion | |||
| Mark Ginsberg (La Jolla, CA) | Dynamic regulation of cell-cell adhesion | ||
| Novel Approaches to Understanding Platelet Biology | |||
| Angel Garcia (Santiago de Compostela, ES) | Novel strategies in platelet research : The proteomics approach | ||
| Platelets and Systemic Disorders | |||
| David Phillips (South San Francisco, CA) | New directions in antithrombotic drug discovery | ||
| Megakaryocytes and Thrombopoiesis | |||
| John Hartwig (Boston, MA) | Megakarycytes and thrombopoiesis | ||
| Polymorphisms, Heterogeneity and the Mechanisms of Platelet Disorders | |||
| Paul Bray (Philadelphia, PA) | Pathways to variation in platelet reactivity | ||
| ADAMTS13, TTP and Related Disorders | |||
| Jose Lopez (Seattle, WA) | ADAMTS13, TTP and related disorders | ||
| Platelets as Drug Targets | |||
| Christian Gachet (Strasbourg Cedex, FR) | Purinergic and other receptors as targets for old and new drugs | ||
|
|||
| Immunology and Treatment of ITP | |||
| Douglas Cines (Philadelphia, PA) | Controversies in ITP | ||
| Pathophysiology of HIT | |||
| Gowthami Arepally (Durham, NC) | Heparin-induced thrombocytopenia: Insights from murine models | ||
| TTP & ADAMTS13 | |||
| Flora Peyvandi (Milan, IT) | Congenital and acquired TTP | ||
| Platelet Function Tests | |||
| Catherine Hayward (Hamilton, CA) | Platelet function tests in the assessment of bleeding problems | ||
| Platelets and Myeloproliferative Syndromes | |||
| Alessandro Vannucchi (Florence, IT) | Mechanisms of thrombosis in myeloproliferative neoplasms | ||
| Platelet Transfusion | |||
| Sherrill Slichter (Seattle, WA ) | Current advances in platelet transfusion therapy | ||
| Microparticles | |||
| Shosaku Nomura (Osaka, JP) | New outlook in clinical significance of microparticles | ||
| Platelets and Cancer | |||
| Jerry Ware (Little Rock, AK) | The platelet paradigm in cancer | ||
|
|||
| Indications for Thrombophilia Testing in Asymptomatic Family Members | |||
| Saskia Middeldorp (Leiden, NL) | Thrombophilia testing in asymptomatic family members: more harm than good? | ||
| Long-Term Complications of VTE: Epidemiology, Prevention and Treatment/Post-Thrombotic Syndrome | |||
| Susan Kahn (Montreal, CA) | The post-thrombotic syndrome: epidemiology and management | ||
| Estrogens and Vascular Disease: Non-Oral Postmenopausal Hormones and Risk of Thrombosis | |||
| Joseph Emmerich (Paris Cedex, FR) | Estrogens and vascular disease: non-oral postmenopausal hormones and risk of thrombosis | ||
| Best Use of Vena Cava Filters | |||
| Suresh Vedantham (St. Louis, MO) | Best unse of Vena cava filters | ||
| Thrombolysis of Lower Extremity DVT | |||
| Thomas Wakefield (Ann Arbor, MI) | Aggressive therapies for DVT | ||
| Paradoxical Embolus and Treatment of PFO | |||
| Sunichi Homma (New York, NY ) | Paradoxical embolus and treatment of PFO | ||
| Pathogenesis of Pre-Eclampsia | |||
| Ananth Karumanchi (Boston, MA) | Pathogenesis of pre-eclampsia | ||
| Neonatal Stroke | |||
| Neil Goldenberg (Aurora, CO) | Neonatal and childhood arterial ischemic stroke | ||